Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Doxycycline Capsules, 40 mg, to market a generic equivalent of Oracea Capsules, 40 mg, of Galderma Laboratories, L.P. Doxycycline Capsules (RLD Oracea) had estimated annual sales of $215 million in the U.S. (IQVIA MAT September 2022).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
